Intratympanic Dexamethasone for Severe Tinnitus

A randomized, single-blind study from Brasília University Medical School found no advantage for intratympanic dexamethasone injections over a saline placebo for severe, disabling tinnitus. Both solutions produced a similar, temporary improvement in 29-33% of patients, suggesting a strong placebo effect.

Direct Test of a Steroid Injection for Tinnitus

Researchers led by Dr. M.F. Araújo designed a study to directly test a specific clinical question: do steroid injections into the middle ear work for severe tinnitus? The hypothesis was based on the anti-inflammatory properties of dexamethasone. Inflammation within the cochlea, the inner ear’s hearing organ, is a suspected contributor to some forms of tinnitus. By injecting the steroid directly through the eardrum (intratympanically), the team aimed to deliver a high concentration of medication to the suspected site of the problem.

The study focused on 36 patients with severe, disabling tinnitus believed to originate in the cochlea. This specificity is important, as tinnitus can have many causes. The researchers used a rigorous design to ensure their results were reliable.

Methodology: A Rigorous, Single-Blind Trial

The trial was prospective, randomized, and single-blind. Patients were randomly assigned to one of two groups. The treatment group received 0.5 mL of a 4-mg/mL dexamethasone solution injected into their middle ear. The control group received an identical procedure with 0.5 mL of isotonic saline solution. Both groups received one injection per week for four consecutive weeks.

Neither the patients nor the clinicians administering the outcome measures knew which solution was injected; only the physician performing the injection was aware. This single-blind design helps prevent bias in how patients report their symptoms. The primary tool for measuring improvement was a visual analog scale (VAS), where patients mark their tinnitus intensity on a line. The team defined a change of 2 points on this 10-point scale as a significant improvement. Five of the original 36 patients did not complete the protocol or follow-up, leaving 31 for analysis.

Findings: No Difference Between Drug and Placebo

The results were clear and statistically definitive. Immediately after the four-week treatment course, 29% of the ears in the saline (placebo) group showed significant improvement on the VAS. In the dexamethasone group, 33% of ears improved. This difference was not significant.

“There was no advantage in intratympanic injections of dexamethasone over saline solution in the treatment of severe, disabling tinnitus,” the authors concluded. They described the improvement in both groups as a “placebolike” effect. The follow-up data, collected over 13 to 31 months, provided the final, crucial piece of evidence: the few patients who did report initial improvement gradually returned to their pre-treatment level of tinnitus severity over time.

The Powerful Role of Placebo in Tinnitus

The nearly identical response rates highlight a critical factor in tinnitus treatment research: the placebo effect. For a subjective, perception-based condition like tinnitus, the belief that a treatment will work—especially an invasive one like an injection—can lead to real, measurable short-term changes in perception. This study’s design successfully isolated this effect, showing that the act of receiving a focused medical intervention was responsible for the benefit, not the active drug itself. This is a vital consideration for patients evaluating new therapies.

Practical Implications for Treatment Pathways

This study, published in Archives of Otolaryngology–Head & Neck Surgery (PMID: 15723941), provides high-quality evidence that should steer clinical practice. The specific protocol of weekly intratympanic dexamethasone injections over four weeks cannot be recommended as an effective treatment for chronic, severe tinnitus of cochlear origin. It spares patients an invasive, time-consuming, and ultimately ineffective procedure.

The findings redirect the search for effective treatments. They suggest that for established chronic tinnitus, local cochlear inflammation may not be a primary, reversible driver, or that this method of steroid delivery is insufficient. Research efforts may be better focused on central auditory pathways and neural mechanisms, or on multidisciplinary approaches that address the significant distress tinnitus can cause.

This distress is often compounded by other conditions. For instance, the sleep disruption common with severe tinnitus can create a bidirectional cycle that worsens both problems. Furthermore, the hypervigilance and anxiety associated with tinnitus share features with conditions like hyperacusis and anxiety after brain injury, suggesting overlapping management strategies that focus on emotional regulation and habituation may be more fruitful than localized injections.

Conclusion: Evidence Guides Better Care

The work by Araújo, Oliveira, and Bahmad is an example of how robust clinical trials can clarify murky treatment landscapes. By demonstrating a lack of specific efficacy for intratympanic dexamethasone, it prevents the proliferation of an unhelpful treatment. For patients and clinicians, it underscores the importance of seeking and supporting interventions with solid evidence, and of understanding the powerful mind-body interactions at play in hearing disorders. Managing expectations and pursuing comprehensive care strategies that address the whole experience of tinnitus, not just the perceived sound, remains the most supported path forward.